苏格兰批准新的骨髓瘤药物组合,促进生存和降低死亡风险。 Scotland approves new myeloma drug combo, boosting survival and reducing death risk.

苏格兰已经批准了一种新的混合疗法——Blentrep with bortezomib 和 dexamethasone——以治疗无法使用Lenalidomide的复发性或耐用性多重骨髓瘤的成年人。 Scotland has approved a new combination therapy—Blenrep with bortezomib and dexamethasone—for adults with relapsed or refractory multiple myeloma who can’t use lenalidomide. 这种治疗得到临床数据的支持,表明在苏格兰全国保健服务机构有36.6个月的无进展存活期,死亡风险比标准护理低42%。 The treatment, backed by clinical data showing a 36.6-month progression-free survival and a 42% lower risk of death compared to standard care, is now available on NHS Scotland. 它通过直接提供化疗和刺激免疫系统,针对肌瘤细胞。 It targets myeloma cells by delivering chemotherapy directly and stimulating the immune system. 苏格兰医药联合会还批准了其他几项治疗,包括内脏癌、肠道癌和内宫硬化治疗,但由于费用问题,苏格兰医药联合会否决了使用pomalidomide的Blenrep。 The Scottish Medicines Consortium also approved several other treatments, including for endometrial and bowel cancers and endometriosis, though it rejected Blenrep with pomalidomide due to cost concerns.